S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
Biden’s Big Lie… (Ad)pixel
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
Biden’s Big Lie… (Ad)pixel
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
Biden’s Big Lie… (Ad)pixel
Is Braze, Inc Ready To Rocket Higher? 
Many electric vehicles to lose big tax credit with new rules
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
Biden’s Big Lie… (Ad)pixel
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
Biden’s Big Lie… (Ad)pixel
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
Biden’s Big Lie… (Ad)pixel
Is Braze, Inc Ready To Rocket Higher? 
Many electric vehicles to lose big tax credit with new rules
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
Biden’s Big Lie… (Ad)pixel
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
Biden’s Big Lie… (Ad)pixel
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
Biden’s Big Lie… (Ad)pixel
Is Braze, Inc Ready To Rocket Higher? 
Many electric vehicles to lose big tax credit with new rules
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
Biden’s Big Lie… (Ad)pixel
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
Biden’s Big Lie… (Ad)pixel
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
Biden’s Big Lie… (Ad)pixel
Is Braze, Inc Ready To Rocket Higher? 
Many electric vehicles to lose big tax credit with new rules
NASDAQ:EOLS

Evolus - EOLS Stock Forecast, Price & News

$8.46
+0.11 (+1.32%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$8.27
$8.56
50-Day Range
$8.07
$11.04
52-Week Range
$6.51
$14.34
Volume
328,024 shs
Average Volume
528,039 shs
Market Capitalization
$477.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.00

Evolus MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
89.1% Upside
$16.00 Price Target
Short Interest
Bearish
5.21% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.27
Upright™ Environmental Score
News Sentiment
0.07mentions of Evolus in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$34.73 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.50) to $0.20 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars

Medical Sector

578th out of 1,004 stocks

Pharmaceutical Preparations Industry

278th out of 489 stocks


EOLS stock logo

About Evolus (NASDAQ:EOLS) Stock

Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November 2012 and is headquartered in Newport Beach, CA.

Receive EOLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evolus and its competitors with MarketBeat's FREE daily newsletter.

EOLS Stock News Headlines

"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast.
Why Evolus Shares Jumped This Week
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast.
Evolus, Inc.'s (NASDAQ:EOLS) Shift From Loss To Profit
Evolus Third Quarter 2022 Earnings: Revenues Disappoint
This Options Play Could Turn That Frown Upside Down - RealMoney
See More Headlines
Receive EOLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evolus and its competitors with MarketBeat's FREE daily newsletter.

EOLS Company Calendar

Last Earnings
3/08/2023
Today
3/31/2023
Next Earnings (Estimated)
5/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EOLS
Fax
N/A
Employees
167
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$16.00
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+89.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-74,410,000.00
Pretax Margin
-50.01%

Debt

Sales & Book Value

Annual Sales
$148.62 million
Book Value
$0.33 per share

Miscellaneous

Free Float
52,294,000
Market Cap
$477.23 million
Optionable
Optionable
Beta
1.93

Key Executives

  • David MoatazediDavid Moatazedi
    President, Chief Executive Officer & Director
  • Sandra Beaver
    Chief Financial Officer
  • Rui AvelarRui Avelar
    Chief Medical Officer, Head-Research & Development
  • Dan Stewart
    Vice President & General Manager
  • Christos Monovoukas
    Senior Vice President-Corporate Development













EOLS Stock - Frequently Asked Questions

Should I buy or sell Evolus stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EOLS shares.
View EOLS analyst ratings
or view top-rated stocks.

What is Evolus' stock price forecast for 2023?

5 brokerages have issued 1 year price objectives for Evolus' stock. Their EOLS share price forecasts range from $10.00 to $20.00. On average, they expect the company's stock price to reach $16.00 in the next year. This suggests a possible upside of 89.1% from the stock's current price.
View analysts price targets for EOLS
or view top-rated stocks among Wall Street analysts.

How have EOLS shares performed in 2023?

Evolus' stock was trading at $7.51 on January 1st, 2023. Since then, EOLS stock has increased by 12.6% and is now trading at $8.46.
View the best growth stocks for 2023 here
.

When is Evolus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our EOLS earnings forecast
.

How were Evolus' earnings last quarter?

Evolus, Inc. (NASDAQ:EOLS) released its quarterly earnings results on Wednesday, March, 8th. The company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by $0.01. The firm had revenue of $43.65 million for the quarter, compared to analysts' expectations of $43.48 million. Evolus had a negative trailing twelve-month return on equity of 178.39% and a negative net margin of 50.07%.

What ETFs hold Evolus' stock?

ETFs with the largest weight of Evolus (NASDAQ:EOLS) stock in their portfolio include Principal Healthcare Innovators ETF (BTEC), Invesco Nasdaq Biotechnology ETF (IBBQ).ProShares Ultra Nasdaq Biotechnology (BIB) and

What guidance has Evolus issued on next quarter's earnings?

Evolus issued an update on its FY 2023 earnings guidance on Thursday, March, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $180.00 million-$190.00 million, compared to the consensus revenue estimate of $186.62 million.

What is David Moatazedi's approval rating as Evolus' CEO?

1 employees have rated Evolus Chief Executive Officer David Moatazedi on Glassdoor.com. David Moatazedi has an approval rating of 100% among the company's employees. This puts David Moatazedi in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Evolus own?
When did Evolus IPO?

(EOLS) raised $65 million in an initial public offering on Thursday, February 8th 2018. The company issued 5,000,000 shares at a price of $12.00-$14.00 per share. Cantor and Mizuho Securities acted as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

What is Evolus' stock symbol?

Evolus trades on the NASDAQ under the ticker symbol "EOLS."

Who are Evolus' major shareholders?

Evolus' stock is owned by a number of institutional and retail investors. Top institutional investors include First Manhattan Co. (7.14%), Caligan Partners LP (3.09%), Millennium Management LLC (2.59%), Boothbay Fund Management LLC (1.92%), AIGH Capital Management LLC (1.65%) and Stonepine Capital Management LLC (1.48%). Insiders that own company stock include Alphaeon 1 Llc, Crystal Muilenburg, David Moatazedi, David N Gill, Lauren P Silvernail, Medytox Inc, Robert Hayman, Rui Avelar and Vikram Malik.
View institutional ownership trends
.

How do I buy shares of Evolus?

Shares of EOLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evolus' stock price today?

One share of EOLS stock can currently be purchased for approximately $8.46.

How much money does Evolus make?

Evolus (NASDAQ:EOLS) has a market capitalization of $477.23 million and generates $148.62 million in revenue each year. The company earns $-74,410,000.00 in net income (profit) each year or ($1.32) on an earnings per share basis.

How many employees does Evolus have?

The company employs 167 workers across the globe.

How can I contact Evolus?

Evolus' mailing address is 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660. The official website for the company is www.evolus.com. The company can be reached via phone at (949) 284-4555 or via email at ir@evolus.com.

This page (NASDAQ:EOLS) was last updated on 4/1/2023 by MarketBeat.com Staff